Progress in the development of matrix metalloproteinase inhibitors

被引:88
作者
Tu, GuoGang [1 ,2 ]
Xu, WenFang
Huang, HuiMing [2 ]
Li, ShaoHua [2 ]
机构
[1] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Jinan 250012, Peoples R China
[2] NanChang Univ, Coll Med, Dept Pharm, Nanchang 330006, Peoples R China
关键词
matrix metalloproteinases; MMP inhibitors; Zinc-binding groups; cancer; computer-aided drug design; angiogenesis; metastasis; proteases;
D O I
10.2174/092986708784567680
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinases ( MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years. With the failure of these inhibitors in clinical trials, more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs, a brief description of available three-dimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.
引用
收藏
页码:1388 / 1395
页数:8
相关论文
共 40 条
[31]   Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases [J].
Sang, Qing-Xiang Amy ;
Jin, Yonghao ;
Newcomer, Robert G. ;
Monroe, Sara C. ;
Fang, Xuexun ;
Hurst, Douglas R. ;
Lee, Seakwoo ;
Cao, Qiang ;
Schwartz, Mar-Tin A. .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (04) :289-316
[32]  
SANKYO CO LTD, 2001, Patent No. 0123363
[33]   The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors [J].
Skiles, JW ;
Gonnella, NC ;
Jeng, AY .
CURRENT MEDICINAL CHEMISTRY, 2004, 11 (22) :2911-2977
[34]   The design, structure, and therapeutic application of matrix metalloproteinase inhibitors [J].
Skiles, JW ;
Gonnella, NC ;
Jeng, AY .
CURRENT MEDICINAL CHEMISTRY, 2001, 8 (04) :425-474
[35]   On the role of polarizability in QSAR [J].
Verma, RP ;
Kurup, A ;
Hansch, C .
BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (01) :237-255
[36]   Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator [J].
Wang, XY ;
Lee, SR ;
Arai, K ;
Lee, SR ;
Tsuji, K ;
Rebeck, GW ;
Lo, EH .
NATURE MEDICINE, 2003, 9 (10) :1313-1317
[37]  
WARSHAWSKY AM, 2002, Patent No. 6352976
[38]   Vulnerability of mouse cortical neurons to doxorubicin-induced apoptosis is strain-dependent and is correlated with mRNAs encoding Fas, Fas-Ligand, and metalloproteinases [J].
Wetzel, M ;
Tibbitts, J ;
Rosenberg, GA ;
Cunningham, LA .
APOPTOSIS, 2004, 9 (05) :649-656
[39]   Design and synthesis of a series of (2R)-N4-hydroxy-2-(3-hydroxybenzyl)-N1-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors [J].
Yao, WQ ;
Wasserman, ZR ;
Chao, M ;
Reddy, G ;
Shi, E ;
Liu, RQ ;
Covington, MB ;
Arner, EC ;
Pratta, MA ;
Tortorella, M ;
Magolda, RL ;
Newton, R ;
Qian, MX ;
Ribadeneira, MD ;
Christ, D ;
Wexler, RR ;
Decicco, CP .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (21) :3347-3350
[40]   Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: Binding comparison with stromelysin-1 and collagenase-1 [J].
Zhang, XL ;
Gonnella, NC ;
Koehn, J ;
Pathak, N ;
Ganu, V ;
Melton, R ;
Parker, D ;
Hu, SI ;
Nam, KY .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 301 (02) :513-524